標(biāo)題: Titlebook: Biomarkers for Alzheimer’s Disease Drug Development; Robert Perneczky Book 2024Latest edition The Editor(s) (if applicable) and The Author [打印本頁] 作者: 揭發(fā) 時(shí)間: 2025-3-21 19:35
書目名稱Biomarkers for Alzheimer’s Disease Drug Development影響因子(影響力)
書目名稱Biomarkers for Alzheimer’s Disease Drug Development影響因子(影響力)學(xué)科排名
書目名稱Biomarkers for Alzheimer’s Disease Drug Development網(wǎng)絡(luò)公開度
書目名稱Biomarkers for Alzheimer’s Disease Drug Development網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomarkers for Alzheimer’s Disease Drug Development被引頻次
書目名稱Biomarkers for Alzheimer’s Disease Drug Development被引頻次學(xué)科排名
書目名稱Biomarkers for Alzheimer’s Disease Drug Development年度引用
書目名稱Biomarkers for Alzheimer’s Disease Drug Development年度引用學(xué)科排名
書目名稱Biomarkers for Alzheimer’s Disease Drug Development讀者反饋
書目名稱Biomarkers for Alzheimer’s Disease Drug Development讀者反饋學(xué)科排名
作者: exceed 時(shí)間: 2025-3-21 20:25
https://doi.org/10.1007/978-3-531-90385-9have slightly modified the methodology, increasing the glycosylation time and using a high-resolution mass analyzer for the analysis of CSF .-glycans, thus obtaining a high-throughput method (up to 96 samples simultaneously), mass accuracy better than 5?ppm, and the ability to separate and identify isomers.作者: 我吃花盤旋 時(shí)間: 2025-3-22 01:54
https://doi.org/10.1007/978-3-531-90385-9graphy and gas chromatography. These procedures have been optimized for the analysis of multiple biological samples from human patients and transgenic animal models, including blood serum, various brain regions (e.g., hippocampus, cortex, cerebellum, striatum, olfactory bulbs), and other peripheral organs (e.g., liver, kidney, spleen, thymus).作者: tic-douloureux 時(shí)間: 2025-3-22 08:34 作者: GNAT 時(shí)間: 2025-3-22 12:40
Konfliktbearbeitung durch den Europaraterges as a synergistic approach to understand the structural correlates related with specific AD-related biomarkers. In this chapter, we describe the methods used in neuroimaging that will allow researchers to combine data on CSF metabolites with imaging analyses.作者: opalescence 時(shí)間: 2025-3-22 13:54
https://doi.org/10.1007/978-3-663-08073-2erpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here, we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and main proposed quantification methods.作者: 空氣傳播 時(shí)間: 2025-3-22 18:03 作者: Concrete 時(shí)間: 2025-3-23 00:23
Book 2024Latest edition kind of detailed implementation advice that leads to greater success in the lab or clinic.?.Authoritative and practical, .Biomarkers for Alzheimer’s Disease Drug Development, Second Edition. seeks to inspire and inform future efforts to develop effective treatments for this devastating disease..作者: VALID 時(shí)間: 2025-3-23 04:21
https://doi.org/10.1007/978-3-531-90385-9has been optimized to obtain high-quality mass spectra in reflector mode with an optimal signal-to-noise ratio up to . 4800. This method has been successfully adopted to associate specific N-glycome profiles to the early and the advanced phases of Alzheimer’s disease (AD).作者: sperse 時(shí)間: 2025-3-23 07:33 作者: 躺下殘殺 時(shí)間: 2025-3-23 11:38 作者: remission 時(shí)間: 2025-3-23 14:35
https://doi.org/10.1007/978-3-531-92696-4eration of new hypotheses regarding the mechanistic and functional significance of lipid and metabolite alterations in neurodegenerative disorders while also facilitating the discovery of new biomarkers to support drug development.作者: sundowning 時(shí)間: 2025-3-23 20:26 作者: Metamorphosis 時(shí)間: 2025-3-23 22:29
Analysis of Resting-State Functional Magnetic Resonance Imaging in Alzheimer’s Diseasen this chapter, we presented the common methods that have been applied in rs-fMRI literature, focusing on the studies on individuals in the continuum of AD. The key methodological aspects will be addressed that comprise acquiring, processing, and interpreting rs-fMRI data. More, we discussed the current and potential implications of rs-fMRI in AD.作者: browbeat 時(shí)間: 2025-3-24 06:26 作者: Acetabulum 時(shí)間: 2025-3-24 10:01 作者: Cryptic 時(shí)間: 2025-3-24 10:42
Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approachesentia prevention, coordinated global efforts are needed to utilize existing cohorts and resources effectively and efficiently. This chapter provides an overview of current research on risk and protective factors for AD and dementia and discusses the opportunities and challenges associated with population-based approaches.作者: 中止 時(shí)間: 2025-3-24 17:39 作者: Foreshadow 時(shí)間: 2025-3-24 22:02
Mass Spectrometry-Based Metabolomics Multi-platform for Alzheimer’s Disease Researchgraphy and gas chromatography. These procedures have been optimized for the analysis of multiple biological samples from human patients and transgenic animal models, including blood serum, various brain regions (e.g., hippocampus, cortex, cerebellum, striatum, olfactory bulbs), and other peripheral organs (e.g., liver, kidney, spleen, thymus).作者: overrule 時(shí)間: 2025-3-25 02:06
Diffusion Tensor Imaging in Alzheimer’s Studieses examining correlations with behavioral variables is also included. Our main message is to caution against the overinterpretation of diffusion metrics and to favor analyses that focus on regions of interest or major white matter tracts for biomarker studies in AD.作者: Infantry 時(shí)間: 2025-3-25 03:53
Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studieserges as a synergistic approach to understand the structural correlates related with specific AD-related biomarkers. In this chapter, we describe the methods used in neuroimaging that will allow researchers to combine data on CSF metabolites with imaging analyses.作者: 不可知論 時(shí)間: 2025-3-25 08:52 作者: Pandemic 時(shí)間: 2025-3-25 12:50 作者: 流動(dòng)才波動(dòng) 時(shí)間: 2025-3-25 16:05
Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Diseasemarkers is well established, especially for AD CSF-based biomarkers. In this chapter, we provide recommendations for an optimal sample handling protocol for the analysis of blood-based biomarkers specifically for amyloid pathology in AD.作者: 不怕任性 時(shí)間: 2025-3-25 20:51
1064-3745 expertsThis fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanis作者: Hay-Fever 時(shí)間: 2025-3-26 00:24 作者: 開始沒有 時(shí)間: 2025-3-26 05:00 作者: 傳授知識(shí) 時(shí)間: 2025-3-26 10:17 作者: 把…比做 時(shí)間: 2025-3-26 14:17
Methods in Molecular Biologyhttp://image.papertrans.cn/b/image/187796.jpg作者: 諂媚于性 時(shí)間: 2025-3-26 17:52 作者: deceive 時(shí)間: 2025-3-26 22:12
https://doi.org/10.1007/978-3-531-90385-9erlying biological and environmental causes. While certain genetic factors have been associated with AD, and various lifestyle and environmental factors have been linked to dementia risk, the interactions between genes and the environment are not yet fully understood. To identify new avenues for dem作者: geriatrician 時(shí)間: 2025-3-27 04:36 作者: 高度贊揚(yáng) 時(shí)間: 2025-3-27 08:08
https://doi.org/10.1007/978-3-531-90385-9-glycome. N-glycans are released from denatured carboxymethylated glycoproteins by digestion with peptide-N-glycosidase F (PNGase F) and purified using both C18 Sep-Pak. and porous graphitized carbon (PGC) HyperSep? Hypercarb? solid phase extraction (SPE) cartridges. The glycan pool is subsequently 作者: strdulate 時(shí)間: 2025-3-27 12:41
https://doi.org/10.1007/978-3-531-90385-9l need for tools that can detect and diagnose the disease in its early stages. Compared with cerebrospinal fluid (CSF)-based biomarkers or positron emission tomography?(PET), the use of reliable blood-based biomarkers could offer an accessible and minimally invasive method of streamlining diagnosis 作者: 勤勞 時(shí)間: 2025-3-27 15:19
https://doi.org/10.1007/978-3-531-90385-9al systems. In this chapter, we describe methods and tips for the application of a mass spectrometry multi-platform in Alzheimer’s disease research, based on the combination of direct mass spectrometry and orthogonal hyphenated approaches, namely, reversed-phase ultrahigh-performance liquid chromato作者: outskirts 時(shí)間: 2025-3-27 19:25
Konfliktaufl?sung durch Selbstver?nderungdisease. Functional connectivity has been studied with an upward trend in the last two decades, predominantly in AD among other neuropsychiatric disorders, and presents a potential biomarker with various features that might provide unique contributions to foster our understanding of neural mechanism作者: Salivary-Gland 時(shí)間: 2025-3-28 00:35
Konfliktbearbeitung durch den Europarating in Alzheimer’s disease (AD). Our description synthesizes insights not only from?patient populations with AD dementia but also from participants at risk for AD dementia (e.g., amnestic mild cognitive impairment, subjective cognitive decline, or familial AD mutation carriers). A reference to studi作者: 意見一致 時(shí)間: 2025-3-28 04:37 作者: 儀式 時(shí)間: 2025-3-28 07:36
Konfliktbearbeitung durch den Europaratr’s disease (AD) symptomatology has shifted the conceptualization of AD as a .. In addition, magnetic resonance imaging (MRI) enables the study of structural and functional cross-sectional correlates and longitudinal changes in vivo, and therefore, the combination of CSF data and imaging analyses em作者: 兵團(tuán) 時(shí)間: 2025-3-28 11:21 作者: 有權(quán) 時(shí)間: 2025-3-28 16:04 作者: Offensive 時(shí)間: 2025-3-28 21:46 作者: 剝皮 時(shí)間: 2025-3-29 00:13 作者: Lumbar-Stenosis 時(shí)間: 2025-3-29 05:51
https://doi.org/10.1007/978-1-0716-3774-6Digital biomarkers; Neuroimaging analysis; Neurodegenerative disorder; Drug targets; Amyloid-targeting a作者: 后退 時(shí)間: 2025-3-29 09:53 作者: 媒介 時(shí)間: 2025-3-29 14:56 作者: consolidate 時(shí)間: 2025-3-29 17:44
Biomarkers for Alzheimer’s Disease Drug Development作者: 語言學(xué) 時(shí)間: 2025-3-29 23:30 作者: 期滿 時(shí)間: 2025-3-30 00:32 作者: champaign 時(shí)間: 2025-3-30 07:06
Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET ApproachT tracers to image glial reactivity and neuroinflammation. While most research to date has focused on imaging microgliosis, there is an upsurge of interest in imaging reactive astrocytes in the AD .. There is increasing evidence that reactive astrocytes are morphologically and functionally heterogen作者: IRATE 時(shí)間: 2025-3-30 11:08
https://doi.org/10.1007/978-3-531-90385-9t for invasive lumbar puncture or exposure to ionizing radiation. Additionally, they are not easily accessible outside of specialized healthcare settings. Blood-based biomarkers of the core pathological features of AD are being developed, showing promise for less invasive, scalable identification of作者: Highbrow 時(shí)間: 2025-3-30 15:00 作者: 古文字學(xué) 時(shí)間: 2025-3-30 19:08
Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings, there is a shift in focus toward detecting the disease at an early stage. AD is characterized by the accumulation of misfolded amyloid-β (Aβ) and phosphorylated tau proteins in the brain, leading to the formation of senile plaques and neurofibrillary tangles. While a definitive diagnosis of AD can作者: Junction 時(shí)間: 2025-3-30 21:47
Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approacheserlying biological and environmental causes. While certain genetic factors have been associated with AD, and various lifestyle and environmental factors have been linked to dementia risk, the interactions between genes and the environment are not yet fully understood. To identify new avenues for dem作者: 虛弱 時(shí)間: 2025-3-31 04:55
CSF N-Glycomics Using High-Throughput UPLC-ESI Techniques in Alzheimer’s Diseaseglycome. This methodology is based on a commercial equipment developed by WATERS? to speed up N-deglycosylation and N-glycan labeling of glycoproteins of pharmaceutical and biological interest such as monoclonal antibodies. This analytical kit is sold under the trade name of RapiFluor-MS (RFMS). We 作者: Motilin 時(shí)間: 2025-3-31 08:32
CSF N-Glycomics Using MALDI MS Techniques-glycome. N-glycans are released from denatured carboxymethylated glycoproteins by digestion with peptide-N-glycosidase F (PNGase F) and purified using both C18 Sep-Pak. and porous graphitized carbon (PGC) HyperSep? Hypercarb? solid phase extraction (SPE) cartridges. The glycan pool is subsequently
